Device CRO NAMSA rolls into the U.K. with Medvance buyout

Ohio medical device researcher NAMSA is stretching out its European presence with the acquisition of Medvance, snapping up the U.K.-headquartered CRO with hopes of growing its share of the med tech market.

NAMSA has long offered consulting and testing services to developers of medical devices, in vitro diagnostics and combo products, doing business in the U.S., Germany, France and China. Now, after paying an undisclosed sum for Medvance, the CRO can bolster its offerings in regulatory, clinical and resourcing services while amping up its presence in Europe, CEO John Gorski said.

"Having experts across even more geographies will help clients deliver their products even more effectively to the physicians and patients around the world who need them most," Gorski said in a statement.

From here on out, the two will do business as NAMSA Medvance, and Janette Benaddi, CEO of the smaller company, will stay on in an executive role.

NAMSA has been working to expand its global presence over the past year, partnering with South Korea's Medipert to reach clients there and investing in a biocompatibility lab in Lyon, France. Meanwhile, the CRO has upped the capacity of its microbiology lab in California and acquired Minnesota's Integra Group to boost its imaging capabilities in the U.S.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.